|
1
|
Gu Y, Lv H, Zhao J, Li Q, Mu G, Li J,
Wuyang J, Lou G, Wang R, Zhang Y and Huang X: Influence of the
number and interval of treatment cycles on cytokine-induced killer
cells and their adjuvant therapeutic effects in advanced
non-small-cell lung cancer (NSCLC). Int Immunopharmacol.
50:263–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lamb YN and Scott LJ: Osimertinib: A
review in T790M-positive advanced non-small cell lung cancer.
Target Oncol. 12:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Powell AC, Mirhadi AJ, Loy BA, Happe LE,
Long JW, Kren EM and Gupta AK: Presentation at computed tomography
(CT) scan of the thorax and first year diagnostic and treatment
utilization among patients diagnosed with lung cancer. PLoS One.
12:e01813192017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He J, Yu L, Wang CM and Zhou XF: MiR-1275
promotes non-small cell lung cancer cell proliferation and
metastasis by regulating LZTS3 expression. Eur Rev Med Pharmacol
Sci. 22:2680–2687. 2018.PubMed/NCBI
|
|
5
|
Chae YK, Arya A, Iams W, Cruz MR, Chandra
S, Choi J and Giles F: Current landscape and future of dual
anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons
learned from clinical trials with melanoma and non-small cell lung
cancer (NSCLC). J Immunother Cancer. 6:392018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Proto C, Russo Lo G, Corrao G, Ganzinelli
M, Facchinetti F, Minari R, Tiseo M and Garassino MC: Treatment in
EGFR-mutated non-small cell lung cancer: How to block the receptor
and overcome resistance mechanisms. Tumori. 103:325–337. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Botsa EI, Thanou IL, Papatheodoropoulou AT
and Thanos LI: Thermal ablation in the management of adrenal
metastasis originating from Non-small cell lung cancer: A 5-year
Single-center experience. Chin Med J (Engl). 130:2027–2032. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang G, Zhang D, Wu J, Zhang F, Zhu Z,
Chen K, Zhang N, Jin J, Feng J, Lin N, et al: Low serum levels of
Pre-surgical total cholesterol are associated with unfavorable
overall survival in patients with operable Non-small cell lung
cancer. Clin Lab. 64:321–327. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Camidge DR, Kim DW, Tiseo M, Langer CJ,
Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, et
al: Exploratory analysis of brigatinib activity in patients with
anaplastic lymphoma Kinase-positive Non-small-cell lung cancer and
brain metastases in two clinical trials. J Clin Oncol:
JCO2017775841. 2018. View Article : Google Scholar
|
|
10
|
Xu Y, Zhang F, Pan X, Wang G, Zhu L, Zhang
J, Wen D and Lu S: Xenograft tumors derived from malignant pleural
effusion of the patients with non-small-cell lung cancer as models
to explore drug resistance. Cancer Commun (Lond). 38:192018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou J, Yu Y, Pei Y, Cao C, Ding C, Wang
D, Sun L and Niu G: A potential prognostic biomarker SPC24 promotes
tumorigenesis and metastasis in lung cancer. Oncotarget.
8:65469–65480. 2017.PubMed/NCBI
|
|
12
|
Ali A, Kim SH, Kim MJ, Choi MY, Kang SS,
Cho GJ, Kim YS, Choi JY and Choi WS: O-GlcNAcylation of NF-κB
promotes lung metastasis of cervical cancer cells via upregulation
of CXCR4 expression. Mol Cells. 40:476–484. 2017.PubMed/NCBI
|
|
13
|
Casaluce F, Sgambato A, Maione P, Sacco
PC, Santabarbara G and Gridelli C: Selumetinib for the treatment of
non-small cell lung cancer. Expert Opin Investig Drugs. 26:973–984.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shlomi D, Abud M, Liran O, Bar J, Gai-Mor
N, Ilouze M, Onn A, Ben-Nun A, Haick H and Peled N: Detection of
lung cancer and EGFR mutation by electronic nose system. J Thorac
Oncol. 12:1544–1551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee WY, Chen PC, Wu WS, Wu HC, Lan CH,
Huang YH, Cheng CH, Chen KC and Lin CW: Panobinostat sensitizes
KRAS-mutant non-small-cell lung cancer to gefitinib by targeting
TAZ. Int J Cancer. 141:1921–1931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma W, Brodie S, Agersborg S, Funari VA and
Albitar M: Significant improvement in detecting BRAF, KRAS, and
EGFR mutations using Next-generation sequencing as compared with
FDA-cleared kits. Mol Diagn Ther. 21:571–579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh PK and Silakari O: Novel EGFR
(T790M)-cMET dual inhibitors: Putative therapeutic agents for
non-small-cell lung cancer. Future Med Chem. 9:469–483. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Tang M, Ou L, Hou M, Feng T, Huang
YE, Jin Y, Zhang H and Zuo G: Biological analysis of cancer
specific microRNAs on function modeling in osteosarcoma. Sci Rep.
7:53822017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Zhang B, Zheng W, Kang M, Chen Q,
Qin W, Li C, Zhang Y, Shao Y and Wu Y: Exosomes derived from
pancreatic cancer cells induce insulin resistance in C2C12 myotube
cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 7:53842017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farooqi AA, Shu CW, Huang HW, Wang HR,
Chang YT, Fayyaz S, Yuan SF, Tang JY and Chang HW: TRAIL, Wnt,
sonic hedgehog, TGFβ, and miRNA signalings are potential targets
for oral cancer therapy. Int J Mol Sci. 18:pii: E15232017.
View Article : Google Scholar
|
|
21
|
Li S, Zhang H, Ning T, Wang X, Liu R, Yang
H, Han Y, Deng T, Zhou L, Zhang L, et al: MiR-520b/e regulates
proliferation and migration by simultaneously targeting EGFR in
gastric cancer. Cell Physiol Biochem. 40:1303–1315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasukawa M, Kawaguchi T, Kawai N, Tojo T
and Taniguchi S: Prognostic significance of mode of nodal
involvement in pulmonary pN1 squamous cell carcinoma. Kyobu Geka.
71:163–168. 2018.(In Japanese). PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nia ES, Garland LL, Eshghi N, Nia BB,
Avery RJ and Kuo PH: Incidence of brain metastases on follow-up
18F-FDG PET/CT scans of non-small cell lung cancer
patients: Should we include the brain? J Nucl Med Technol.
45:193–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang Y, Xu X, Wang T, Li Y, You W, Fu J,
Liu Y, Jin S, Ji Q, Zhao W, et al: The EGFR/miR-338-3p/EYA2 axis
controls breast tumor growth and lung metastasis. Cell Death Dis.
8:e29282017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H,
Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673
regulated non-small cell lung cancer proliferation, migration,
invasion and epithelial mesenchymal transition by sponging
miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuwen DL, Sheng BB, Liu J, Wenyu W and Shu
YQ: MiR-146a-5p level in serum exosomes predicts therapeutic effect
of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol
Sci. 21:2650–2658. 2017.PubMed/NCBI
|
|
28
|
Lu Y, Tang L, Zhang Q, Zhang Z and Wei W:
MicroRNA-613 inhibits the progression of gastric cancer by
targeting CDK9. Artif Cells Nanomed Biotechnol. 46:980–984. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moles R: MicroRNAs-based therapy: A novel
and promising strategy for cancer treatment. Microrna. 6:102–109.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian H, Yang C and Yang Y: MicroRNA-26a
inhibits the growth and invasiveness of malignant melanoma and
directly targets on MITF gene. Cell Death Discov. 3:170282017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng Z, Qu JQ, Yi HM, Ye X, Huang W, Xiao
T, Li JY, Wang YY, Feng J, Zhu JF, et al: MiR-125b regulates
proliferation and apoptosis of nasopharyngeal carcinoma by
targeting A20/NF-kappaB signaling pathway. Cell Death Dis.
8:e28552017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Muralimanoharan S, Guo C, Myatt L and
Maloyan A: Sexual dimorphism in miR-210 expression and
mitochondrial dysfunction in the placenta with maternal obesity.
Int J Obes (Lond). 39:1274–1281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang L, Zhao Z, Zheng L, Xue L, Zhan Q
and Song Y: Downregulation of miR-503 promotes ESCC cell
proliferation, migration, and invasion by targeting cyclin D1.
Genomics Proteomics Bioinformatics. 15:208–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang X, Yin J, Xiang Q, Xie H, Yu J, Gan R
and Lei X: MiR-503 sensitizes human hepatocellular carcinoma cells
to cisplatin by targeting bcl-2. Zhong Nan Da Xue Xue Bao Yi Xue
Ban. 42:605–610. 2017.(In Chinese). PubMed/NCBI
|
|
36
|
Lu YC, Cheng AJ, Lee LY, You GR, Li YL,
Chen HY and Chang JT: MiR-520b as a novel molecular target for
suppressing stemness phenotype of head-neck cancer by inhibiting
CD44. Sci Rep. 7:20422017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiao J, Li G, Zhou J, Wang S, Liu D, Shu
G, Zhou J and Ren F: MicroRNA-520b functions as a tumor suppressor
in colorectal cancer by inhibiting DCUN1D1. Oncol Res. May
4–2017.(Epub ahead of print). View Article : Google Scholar
|
|
38
|
Xiong F, Liu K, Zhang F, Sha K, Wang X,
Guo X and Huang N: MiR-204 inhibits the proliferation and invasion
of renal cell carcinoma by inhibiting RAB22A expression. Oncol Rep.
35:3000–3008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Z, He M, Wang K, Sun G, Tang L and Xu
Z: Tumor suppressive microRNA-193b promotes breast cancer
progression via targeting DNAJC13 and RAB22A. Int J Clin Exp
Pathol. 7:7563–7570. 2014.PubMed/NCBI
|
|
40
|
Wang T, Gilkes DM, Takano N, Xiang L, Luo
W, Bishop CJ, Chaturvedi P, Green JJ and Semenza GL:
Hypoxia-inducible factors and RAB22A mediate formation of
microvesicles that stimulate breast cancer invasion and metastasis.
Proc Natl Acad Sci USA. 111:E3234–E3242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Su F, Chen Y, Zhu S, Li F, Zhao S, Wu L,
Chen X and Su J: RAB22A overexpression promotes the tumor growth of
melanoma. Oncotarget. 7:71744–71753. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou Y, Wu B, Li JH, Nan G, Jiang JL and
Chen ZN: Rab22a enhances CD147 recycling and is required for lung
cancer cell migration and invasion. Exp Cell Res. 357:9–16. 2017.
View Article : Google Scholar : PubMed/NCBI
|
